USPTO serial 79249944
HYA
Reviewed by CopyMark Law Group
Reg. 5929291Status 709
- Filing date
- Status date
- Registration date
- Dec 10, 2019
- Examiner
- VAGHANI, MAYUR C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with HYA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
NITTO PHARMACEUTICAL INDUSTRIES, LTD.
JP
Other trademarks owned by NITTO PHARMACEUTICAL INDUSTRIES, LTD.
NITTO PHARMACEUTICAL INDUSTRIES, LTD.
JP
Other trademarks owned by NITTO PHARMACEUTICAL INDUSTRIES, LTD.
NITTO PHARMACEUTICAL INDUSTRIES, LTD.
JP
Other trademarks owned by NITTO PHARMACEUTICAL INDUSTRIES, LTD.
JP
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, namely, chemical additives for use in the manufacture of food, pharmaceuticals, cosmetics and animal feed; perfluorinated chemical compounds prepared synthetically for use in the manufacture of cosmetics and pharmaceuticals; food preserving chemicals; chemical preparations for preserving foodstuffs; chemical products for the fresh-keeping and preserving of food; chemical products for stabilizing foodstuffs; chemicals for industrial purposes; chemicals for use in the manufacture of a wide variety of goods; glue and adhesives for industrial purposes; plant growth regulating preparations; fertilizers; higher fatty acids for industrial purposes; chemical compositions for developing, printing and enlarging photographs; unprocessed plastics | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations other than for agricultural purposes for the treatment and prevention of metabolic and endocrine diseases, namely, diabetes, diabetic complication, hyperlipidemia, hyperuricemia, gout, lifestyle related disease, nutritional disorders, impaired glucose tolerance, metabolic syndrome, obesity and lipid disorder, cardiovascular, urological and reproductive diseases, namely, hypertension, hyperglycemia, ischemic heart disease, hyperinsulinemia, arteriosclerosis, myocardial infarction, angina pectoris, aneurysm, chronic kidney disease, renal calculi, kidney disease, pyelonephritis, nephritis, urethritis, cystitis, hypercholesterolemia and high triglyceridemia, respiratory diseases, namely, bronchitis, pulmonary emphysema and lung inflammation, digestive and oral diseases, namely, abnormality of the intestinal flora, abdominal distension, peptic ulcer, intestinal disease, inflammatory disorder, irritable bowel syndrome, gastric ulcer, inflammatory bowel disease, Crohn's disease, diverticulitis, liver cirrhosis, fatty liver, diarrhea, constipation, loose stool disease, hepatic inflammation, non-alcoholic steatohepatitis, viral hepatitis, alcoholic hepatitis, dental disease, periodontal diseases, stomatitis, xerostomia and cyst, immune, inflammatory and allergic diseases, namely, immune related diseases and abnormalities, type I, II, III, IV and V allergy, pollinosis, atopic dermatitis, psoriasis, autoimmune disease and connective tissue disease, bone and articular diseases, namely, rheumatism, osteoporosis and articular inflammation, pathogenic microbial and malignant neoplastic diseases, namely, infection, cancer and malignant tumor, mental and nervous system diseases, namely, mental disorder, dementia, Alzheimer's disease, bipolar disorder, depression, anorexia, insomnia, cerebral apoplexy, cerebral infarction, autism, neuroinflammation, overwork related disease and nerve inflammation related diseases and cancers resulting from chronic inflammation, and sensory system and skin diseases, namely, ophthalmic disease, ocular inflammation, otorhinolaryngology disease and skin inflammation; pharmaceutical preparations in the nature of medicines for dental purposes; reagent paper for medical purposes; oiled paper for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceutical for medicine doses; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages; antiseptic liquid bandages; breast-nursing pads; dental composite, impression and porcelain materials; dental materials, namely, dental porcelain materials, materials for making dental impressions and composite materials for dental and dental technical purposes; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; beverages for babies, namely, human breast milk, powdered milk, isotonic beverages for babies; food for babies; dietary supplements for animals | SECTION 71 - CANCELLED | — |
| 016 | Paper and cardboard; printed matter, namely, paper signs, books, manuals, curricula, newsletters, information cards and brochures in the field of health | SECTION 71 - CANCELLED | — |
| 035 | Advertising and publicity services | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NITTO PHARMACEUTICAL INDUSTRIES, LTD.
- Other trademarks owned by NITTO PHARMACEUTICAL INDUSTRIES, LTD.
- Other trademarks owned by NITTO PHARMACEUTICAL INDUSTRIES, LTD.
- Other trademarks owned by Noster Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 016
- Other trademarks in Class 035
- Similar marks named HYA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 26, 2026 | C71T | CANCELLED SECTION 71 | — |
| Dec 10, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 12, 2021 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Apr 10, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 24, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 24, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 10, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 10, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 5, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 24, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 24, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 18, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 18, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 4, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 19, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 25, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 25, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 22, 2019 | ALIE | ASSIGNED TO LIE | — |
| Jul 17, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 17, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 2, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 8, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 8, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 29, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 26, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 25, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 25, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 24, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |